KAPA
AMEXKairos Pharma Ltd.
Kairos Pharma Ltd. (KAPA) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 4 wire items for KAPA, including 2 press releases and news items and 2 SEC filings. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Net income, TTM
- -$5.80M
- Cash
- $2.63M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks21-50%
2026-05-102026-11-01
Mix1090d
- SEC Filings5(50%)
- Other5(50%)
Latest news
25 items- SECKairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug DevelopmentHouston conference serves as a platform devoted to advancing the field of basic, preclinical, and translational cancer research Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, announces that Neil Bhowmick, President and Chief Scientific Officer, presents today on Kairos Pharma’s lead candidate ENV-105 and its interim efficacy results at the United Scientific Group’s 11th International Conference on Cancer Research & Drug Development (Cancer R&D 2026) in Houston, TX. Kairos Pharma’s current programs with ENV-105, a first-in-class CD105/BMP signaling inhibitor, include a Phase 1 trial in EGFR-driven non-small cell lung canc
- SECSEC Form 8-K filed by Kairos Pharma Ltd.8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate CancerKairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone. Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008). With the interim efficacy sig
- PRKairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MAKairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website. Bhowmick will moderate an in-person only breakout session on Sept. 30 titled, "Winning the Race against Cancer Therapy Resistance," focused on Kairos’ primary strategy of targeting cancer drug resistance for patients with high unmet need in o
- SECKairos Pharma Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceKairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Presentation Date: September 14, 2026 Time: 4:00 PM Eastern Time (Holmes 1) Webcast Link: Available Here A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days. Dr. Yu will be av
- SECKairos Pharma Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Announces 1-for-7 Reverse Stock SplitKairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the "Effective Time"), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol "KAPA" and a new CUSIP number of 48301N203. In connection with the Reverse Stock Split, every seven (7) shares of the Company’s common stock issued an
- SECSEC Form 10-Q filed by Kairos Pharma Ltd.10-Q - Kairos Pharma, LTD. (0001962011) (Filer)
- SECKairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate CancerCombination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castr
- SECKairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form 8-K filed by Kairos Pharma Ltd.8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- SECKairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form DEFA14A filed by Kairos Pharma Ltd.DEFA14A - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form DEF 14A filed by Kairos Pharma Ltd.DEF 14A - Kairos Pharma, LTD. (0001962011) (Filer)
- SECKairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical AwardCompany selected for the Leaders in Drug Resistance Development award Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Leaders in Drug Resistance Development 2026 - USA award recipient. Following a merit-led research and evaluation process by GHP's expert research and judging team, based on innovation, impact, business performance and contribution to patient outcomes, Kairos Pharma has been recognized as a leader in the research and development to combat drug resistance. "Drug resistance can no longer be an af
- SECSEC Form 10-Q filed by Kairos Pharma Ltd.10-Q - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form PRE 14A filed by Kairos Pharma Ltd.PRE 14A - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual FilingsKairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders. The Company also advises its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming
- PRKairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare InnovationCompany selected as an Emerald honoree for Innovator of Biotech Solutions Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as an Emerald honoree for Innovator of Biotech Solutions for addressing cancer drug resistance. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer th
- SECSEC Form 424B3 filed by Kairos Pharma Ltd.424B3 - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form 424B3 filed by Kairos Pharma Ltd.424B3 - Kairos Pharma, LTD. (0001962011) (Filer)
KAPA FAQ
8 questionsWhat is the latest news on KAPA?
In the last 30 days Quantisnow tracked 4 wire items for KAPA: 2 press releases and news items and 2 SEC filings. The most recent was published on November 3, 2026.Is KAPA profitable?
No. Kairos Pharma Ltd. reported a net loss of $5.80M for the twelve months ended Jun 30, 2026.How much cash and debt does KAPA have?
Kairos Pharma Ltd. reported $2.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does KAPA stock trade?
Kairos Pharma Ltd. (KAPA) is listed on AMEX.What sector and industry is KAPA in?
Kairos Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kairos Pharma Ltd. go public?
Kairos Pharma Ltd. (KAPA) completed its IPO in 2024.What companies are similar to KAPA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KAPA side-by-side with any of them on Quantisnow.How can I track KAPA on Quantisnow?
Quantisnow aggregates Kairos Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KAPA to receive live email and push alerts on every new disclosure.